Corcept Oncology Chief Sells at $100 After $6M Exit
Roberto Wandenkolk Vieira, Corcept's President of Oncology, sold shares at $100.82 on September 16 — the lowest price in a 90-day insider selling wave totaling $32.54M — even as the company's most rec
Corcept Oncology Chief Sells at $100 After $6M Exit
NEW YORK, September 20 —
Corcept Therapeutics Incorporated (CORT) delivered a 529.4% EPS beat in its most recent quarter and reached 2026 stock highs on relacorilant pipeline momentum, but the company's President of Oncology has now sold shares twice, returning September 16 at $100.82, the lowest open-market price recorded by any insider in a 90-day selling window with zero purchases.
- TTM revenue $830M, up 31.7% year-over-year; Q2 2026 EPS of $0.36 beat the consensus by 529.4%.
- Insiders sold $32.54M in open-market shares over the trailing 90 days per Form 4 filings, with zero purchases.
- Stock at $110.29, forward P/E 25.1x; consensus analyst target $141; HC Wainwright maintains $165.
The Beat That Followed Two Misses
Corcept markets Korlym, an oral cortisol blocker for Cushing's syndrome patients who have failed surgery or are not surgical candidates, and is advancing relacorilant, whose NDA resubmission drove the stock to 2026 highs, alongside miricorilant for MASH and two ALS candidates. The Q2 beat, reported via the July 29 earnings 8-K, arrived between a 39.4% EPS miss in Q4 2025 and a 112.7% miss in Q1 2026; Q3 2025 was the only other beat in the four-quarter window. A 98.3% gross margin and $310M in cash against $10M in debt are structural strengths; 11.2% short interest marks a significant bearish position still open in the stock.
Insiders Sold the High and Kept Selling Lower
Per Form 4 filings, the window's highest open-market insider price was $126.06, recorded by Sean Maduck on August 25; he also sold at $125.47 that day and returned September 1 at $113.94 to $115.61 for $2.86M more. Kimberly Park sold 26,685 shares at $122.55 on August 26 for $3.27M. David L. Mahoney's four-tranche August 18 exit totaled over $12.25M, with the largest single tranche producing $10.78M at $118.24. Roberto Wandenkolk Vieira, President of Oncology, sold 57,863 shares across seven tranches on September 2 at $109 to $115, generating $6.46M after first exercising 58,333 options at $21.63.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| CORT | $11.9B | 25.1x | +37.9% |
| CYTK | $9.6B | n/a | +42.5% |
| SUPN | $2.4B | 9.4x | -10.6% |
| HALO | $12.8B | 10.8x | +43.7% |
| VNDA | $310M | 25.6x | +8.0% |
| INVA | $1.5B | 9.6x | +11.0% |
What Comes Next, and What Would Move the Thesis
On September 16, Vieira returned to sell an additional 296 shares at $100.82, the lowest open-market insider sale price in the window, two days after Joseph Douglas Lyon sold 10,000 shares at $113 to $114 and one day after James N. Wilson sold 10,000 shares at $110 to $112. At $110.29 and 25.1x forward earnings, the stock trades against a consensus analyst target of $141 and HC Wainwright's $165. The relacorilant regulatory process is the primary near-term catalyst; a second consecutive earnings beat would be the clearest test of whether the alternating-beat pattern has broken. Run the free Corcept Therapeutics Incorporated deep-dive →
Current fundamentals, valuation and filing history for Corcept Therapeutics Incorporated (CORT) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Roberto Wandenkolk Vieira, Corcept's President of Oncology, sold shares at $100.82 on September 16 — the lowest price in a 90-day insider selling wave totaling $32.54M — even as the company's most recent quarter delivered a 529.4% EPS beat and the stock reached 2026 highs on relacorilant pipeline momentum as recently as late August.